Premium
The inotropic effects of UK 14,275, a phosphodiesterase inhibitor, in man.
Author(s) -
Jackson PG,
Jackson G,
Kitson D,
Jewitt DE
Publication year - 1978
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1978.tb01591.x
Subject(s) - inotrope , chronotropic , propranolol , isoprenaline , medicine , phosphodiesterase , phosphodiesterase inhibitor , practolol , enoximone , dobutamine , endocrinology , pharmacology , heart rate , blood pressure , chemistry , hemodynamics , stimulation , enzyme , biochemistry
1. UK 14,275 (Pfizer) an inotropic agent with cardiac phosphodiesterase inhibitory activity, was administered to ten healthy male volunteers. 2. The inotropic activity was assessed by non‐invasive measurement of systolic time intervals (STI). 3. The compound had significant inotropic activity in the doses administered, as judged by the shortening of pre‐ejection period (PEP), without any significant chronotropic activity. 4. The inotropic effect was abolished when measurements were repeated following beta‐adrenoceptor blockade with oral propranolol. 5. The inotropic activity was compared to that of intravenous isoprenaline.